Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Spanish reimbursement system

- PMLiVE

Brexit: Implications for the pharma industry

From patents to the EMA, data protection to clinical trials, there's a lot that should be a concern

- PMLiVE

AbbVie’s PARP inhibitor veliparib fails to deliver

Phase III trials show no increase in clinical benefit

- PMLiVE

Verily’s Baseline health project seeks 10,000 volunteers

Four-year study to produce a molecular snapshot

Roche Basel Switzerland

Roche claims another FDA green light for Tecentriq

Wins approval for the treatment's first-line use in bladder cancer

Can UK pharma rise to the post-Brexit challenge?

Our dominant and thriving industry is one we should be proud of

- PMLiVE

Ipsen appoints executive vice president

Alexandre Lebeaut also set to be chief scientific officer

Top tips for “digitally cautious” pharma

Some practical ways to enter this new era of customer and patient-centricity

- PMLiVE

Circassia exits allergy R&D after placebo effect strikes again

Abandons phase IIb trial of house dust mite allergy candidate

- PMLiVE

Blossoming creative services at Porterhouse Medical

The team at Porterhouse Medical is delighted to announce the promotion of Richard Oakham to the role of Creative Services Manager. Since joining our agency last September, Richard has made a very positive...

Porterhouse Medical Group

- PMLiVE

Being indifferent matters

Relying on indifference in the health system

- PMLiVE

Unhappy times continue at OncoMed with more disappointing results

Lung cancer candidate tarextumab fails phase II trial

Eli Lilly HQ

FDA turns down Lilly and Incyte JAK inhibitor after delay

Analysts suggest safety issues in high doses

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links